Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2”

174 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 174 results

Not applicableStudy completedNCT04257474
What this trial is testing

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 265
Testing effectiveness (Phase 2)Looking for participantsNCT05806515
What this trial is testing

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Who this might be right for
Prostate AdenocarcinomaStage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8
SWOG Cancer Research Network 44
Not applicableStudy completedNCT04683068
What this trial is testing

Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing

Who this might be right for
BRCA1 MutationBRCA2 MutationPsychosocial Factors
European Institute of Oncology 264
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Testing effectiveness (Phase 2)Study completedNCT00753545
What this trial is testing

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
AstraZeneca 265
Not applicableActive Not RecruitingNCT05939128
What this trial is testing

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Who this might be right for
Breast Cancer
AstraZeneca 625
Early research (Phase 1)Study completedNCT01339650
What this trial is testing

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian TubePrimary Peritoneal CancerSolid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
AbbVie (prior sponsor, Abbott) 93
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Not applicableUnknownNCT01907438
What this trial is testing

Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Hadassah Medical Organization 30
Not applicableStudy completedNCT03119285
What this trial is testing

Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families

Who this might be right for
Ovarian Cancer
University of Washington 34
Not applicableLooking for participantsNCT07532434
What this trial is testing

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

Who this might be right for
Ovarian CancerBreast Cancer
Peking University Third Hospital 480
Not applicableStudy completedNCT02514499
What this trial is testing

Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Who this might be right for
BRCA1/2 Negative
Abramson Cancer Center at Penn Medicine 350
Testing effectiveness (Phase 2)Study completedNCT01333748
What this trial is testing

Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Centre Francois Baclesse 530
Post-approval studies (Phase 4)Study completedNCT04330040
What this trial is testing

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Who this might be right for
Ovarian CancerBreast Cancer
AstraZeneca 202
Large-scale testing (Phase 3)UnknownNCT03162276
What this trial is testing

Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer Syndrome
Sheba Medical Center 118
Not applicableNot Yet RecruitingNCT06726330
What this trial is testing

Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

Who this might be right for
Tubo-ovarian CarcinomaHigh-grade Serous CarcinomaPrimary Peritoneal Carcinoma Stage III+2 more
Centre Oscar Lambret 1,100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Testing effectiveness (Phase 2)Active Not RecruitingNCT03480776
What this trial is testing

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Who this might be right for
Ovarian Cancer Prevention
Canadian Cancer Trials Group 117
Testing effectiveness (Phase 2)Looking for participantsNCT07321015
What this trial is testing

A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance

Who this might be right for
Platinum-sensitiveTNBC, Triple Negative Breast CancerBRCA1/2 Mutation or Not
Tianjin Medical University Cancer Institute and Hospital 72
Not applicableLooking for participantsNCT06817694
What this trial is testing

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Who this might be right for
Breast Cancer Susceptibility Gene (BRCA1) MutationBRCA2 MutationFear of Cancer Recurrence
CHU de Quebec-Universite Laval 250
Next Page